Ketorolac — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Acute Musculoskeletal Pain

• Ibuprofen
• Naproxen
• Tramadol

Also listed for Chronic Pain

• Gabapentin
• Pregabalin
• Celecoxib
• Diclofenac
• Duloxetine

Other medications in Pain & Inflammation

• Meclofenamate
• Menthol-Methyl Salicylate
• Meperidine
• Metaxalone
• Methadone
• Methocarbamol
• Morphine
• Nabumetone

About Ketorolac

Ketorolac, often recognized by its brand name Toradol, is a potent medication prescribed for the short-term relief of moderate to severe acute pain. While highly effective, prescription costs can be a significant concern. ## What Ketorolac Treats

Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) primarily utilized for the short-term (typically up to five days) management of moderate to severe acute pain. It's a powerful option often prescribed when other pain relievers aren't strong enough or suitable. You might receive a prescription for ketorolac after surgical procedures, for acute injuries, or other conditions where significant pain relief is urgently needed. Its strength means it's not intended for chronic pain conditions but rather for intense, temporary discomfort, helping patients recover more comfortably. ## How Ketorolac Works

Like other NSAIDs, ketorolac works by inhibiting the body's production of certain natural substances called prostaglandins. Prostaglandins play a key role in causing inflammation, pain, and fever. By blocking the enzymes (specifically cyclooxygenase-1 and cyclooxygenase-2, or COX-1 and COX-2) that create prostaglandins, ketorolac effectively reduces both the perception of pain and the inflammatory response. This mechanism makes it highly effective in quickly alleviating severe pain and swelling, allowing you to get back on your feet sooner. ## Typical Costs and TheDrugClub Savings

Without insurance or a robust savings program, the cost of a generic ketorolac prescription can vary significantly. For a typical short course, prices might range anywhere from $20 to over

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ketorolac is approved for (FDA label)

Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Acute Pain in Adult Patients Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary.

Source: Read the full FDA label on DailyMed. Label effective date: September 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Ketorolac (FDA label)

WARNING Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level. Oral ketorolac tromethamine is indicated only as continuation treatment following intravenous or intramuscular dosing of ketorolac tromethamine, if necessary. The total combined duration of use of oral ketorolac tromethamine and ketorolac tromethamine injection should not exceed 5 days. Ketorolac tromethamine is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine beyond the label recommendations will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK • Ketorolac tromethamine can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS ). CARDIOVASCULAR THROMBOTIC EVENTS • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.

Source: FDA prescribing information (DailyMed). Set ID: 2a23b0fa-803c-4abb-b588-12cfe83326a9. SPL document ID: 5aa0cdb6-1dcf-0bba-e063-6394a90a3635. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ketorolac (FDA label)

Adverse reaction rates increase with higher doses of ketorolac tromethamine. Practitioners should be alert for the severe complications of treatment with ketorolac tromethamine, such as G.I. ulceration, bleeding and perforation, postoperative bleeding, acute renal failure, anaphylactic and anaphylactoid reactions and liver failure (see Boxed WARNING , WARNINGS , PRECAUTIONS , and DOSAGE AND ADMINISTRATION ). These NSAID-related complications can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately.

Source: FDA prescribing information (DailyMed). Set ID: 2a23b0fa-803c-4abb-b588-12cfe83326a9. SPL document ID: 5aa0cdb6-1dcf-0bba-e063-6394a90a3635. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ketorolac (FDA label)

( see also Boxed WARNING ) Ketorolac tromethamine is contraindicated in patients with previously demonstrated hypersensitivity to ketorolac tromethamine. Ketorolac tromethamine is contraindicated in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Ketorolac tromethamine should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see WARNINGS – Anaphylactoid Reactions , and PRECAUTIONS – Pre-existing Asthma ). Ketorolac tromethamine is contraindicated as prophylactic analgesic before any major surgery. Ketorolac tromethamine is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS ).

Source: FDA prescribing information (DailyMed). Set ID: 2a23b0fa-803c-4abb-b588-12cfe83326a9. SPL document ID: 5aa0cdb6-1dcf-0bba-e063-6394a90a3635. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ketorolac (FDA label)

Ketorolac is highly bound to human plasma protein (mean 99.2%). There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs. Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 mcg/mL. Ketorolac does not alter digoxin protein binding. In vitro studies indicate that, at therapeutic concentrations of salicylate (300 mcg/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential two-fold increase in unbound ketorolac plasma levels. Therapeutic concentrations of digoxi n , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin and tolbutamide did not alter ketorolac tromethamine protein binding.

Source: FDA prescribing information (DailyMed). Set ID: 2a23b0fa-803c-4abb-b588-12cfe83326a9. SPL document ID: 5aa0cdb6-1dcf-0bba-e063-6394a90a3635. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.